Comparison 12. H2 receptor antagonists versus anticholinergics.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clinically important upper GI bleeding	3	556	Risk Ratio (M‐H, Fixed, 95% CI)	1.37 [0.58, 3.26]
1.1 Cimetidine vs pirenzepine	1	55	Risk Ratio (M‐H, Fixed, 95% CI)	1.45 [0.26, 7.99]
1.2 Ranitidine vs pirenzepine	2	501	Risk Ratio (M‐H, Fixed, 95% CI)	1.35 [0.50, 3.67]
2 Nosocomial pneumonia	3	544	Risk Ratio (M‐H, Fixed, 95% CI)	0.96 [0.50, 1.84]
2.1 Famotidine vs pirenzepine	1	43	Risk Ratio (M‐H, Fixed, 95% CI)	0.32 [0.01, 7.42]
2.2 Ranitidine vs pirenzepine	2	501	Risk Ratio (M‐H, Fixed, 95% CI)	1.03 [0.53, 2.01]
3 All‐cause mortality in ICU	2	501	Risk Ratio (M‐H, Random, 95% CI)	0.89 [0.21, 3.87]
3.1 Ranitidine vs pirenzepine	2	501	Risk Ratio (M‐H, Random, 95% CI)	0.89 [0.21, 3.87]
4 Number of participants requiring blood transfusion	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4.1 Ranitidine vs pirenzepine	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
5 Adverse events of interventions	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
5.1 Tachycardia	1	55	Risk Ratio (M‐H, Fixed, 95% CI)	0.11 [0.01, 1.90]
5.2 High temperature	1	43	Risk Ratio (M‐H, Fixed, 95% CI)	0.53 [0.21, 1.32]